Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Prime Capital Investment Advisors LLC

Prime Capital Investment Advisors LLC reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.8% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 15,449 shares of the biopharmaceutical company’s stock after selling 1,123 shares during the quarter. Prime Capital Investment Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $11,715,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in the company. Tred Avon Family Wealth LLC raised its position in shares of Regeneron Pharmaceuticals by 24.7% in the third quarter. Tred Avon Family Wealth LLC now owns 662 shares of the biopharmaceutical company’s stock worth $502,000 after acquiring an additional 131 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd boosted its stake in shares of Regeneron Pharmaceuticals by 6.4% during the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 15,171 shares of the biopharmaceutical company’s stock worth $11,504,000 after acquiring an additional 911 shares in the last quarter. Drum Hill Capital LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at about $227,000. Highland Financial Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at about $236,000. Finally, Abel Hall LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at about $217,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Kathryn Guarini sold 400 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $340,000.00. Following the transaction, the director owned 603 shares in the company, valued at $512,550. This trade represents a 39.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Andrew J. Murphy sold 4,147 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total value of $3,204,386.90. Following the completion of the sale, the insider directly owned 47,833 shares in the company, valued at $36,960,559.10. This represents a 7.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 8,093 shares of company stock valued at $6,506,845 in the last 90 days. Corporate insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 3.3%

REGN stock opened at $807.48 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $572.75 and a 52 week high of $859.34. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The firm has a 50-day simple moving average of $791.41 and a 200-day simple moving average of $721.87. The stock has a market capitalization of $83.14 billion, a P/E ratio of 19.96, a P/E/G ratio of 1.35 and a beta of 0.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. The firm had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. Regeneron Pharmaceuticals’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same period last year, the company posted $12.81 EPS. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 47.98 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were paid a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date was Tuesday, August 18th. Regeneron Pharmaceuticals’s payout ratio is 9.29%.

Analyst Ratings Changes

Several equities analysts recently weighed in on REGN shares. Leerink Partners lifted their price target on Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the company a “market perform” rating in a research note on Monday, August 17th. Morgan Stanley increased their price target on Regeneron Pharmaceuticals from $758.00 to $779.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 7th. Wall Street Zen raised Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 20th. Zacks Research raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, September 28th. Finally, Citigroup boosted their price objective on Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the company a “neutral” rating in a research report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $845.59.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.